On April 11, 2023, Greg Garfield notified NeuroPace, Inc. that he will not stand for reelection as a director to the Board of Directors (the Board") of NeuroPace, Inc. Mr. Garfield informed NeuroPace that his decision to not stand for reelection as a director was not due to any disagreements with NeuroPace on any matter relating to NeuroPace's operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.57 USD | -2.52% | -13.55% | -36.28% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.28% | 188M | |
+6.02% | 215B | |
+9.25% | 187B | |
+19.58% | 143B | |
+29.74% | 110B | |
+1.63% | 64.68B | |
+15.27% | 52.96B | |
+2.69% | 49.84B | |
-5.47% | 38.32B | |
+1.58% | 35.86B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- NeuroPace, Inc. Announces Resignation of Greg Garfield as Director